Nanosystems for the delivery of RNAi

Therapeutic Ribonucleic Acids in Brain Tumors

Volumn , Issue , 2009, Pages 197-220

  Schulze, Daniel ^a   Aigner, Achim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80755185501     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-00475-9_10     Document Type: Chapter

References (115)

1. Aigner A (2006a) Delivery systems for the direct application of siRNAs to induce RNA Interference (RNAi) in vivo. J Biomed Biotechnol 2006:71659.
2. Aigner A (2006b) Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. J Biotechnol 124:12-25.
3. Aigner A (2007a) Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76:9-21.
4. Aigner A (2007b) Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther 9:345-352.
5. Aigner A, Wolf S, Gassen HG (1997) Transport and detoxication: Principles, approaches, and perspectives for research on the blood-brain barrier. Angew Chem Int Ed Engl 36:24-41.
6. Aigner A, Fischer D, Merdan T et al (2002) Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 9:1700-1707.
7. Akaneya Y, Jiang B, Tsumoto T (2005) RNAi-induced gene silencing by local electroporation in targeting brain region. J Neurophysiol 93:594-602.
8. Behr JP (1997) The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 51:34-36.
9. Bernstein E, Caudy AA, Hammond SM et al (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.
10. Boado RJ (2005) RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx 2:139-150.
11. Boese Q, Leake D, Reynolds A et al (2005) Mechanistic insights aid computational short interfering RNA design. Methods Enzymol 392:73-96.
12. Boussif O, Lezoualc'h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 92:7297-7301.
13. Braasch DA, Jensen S, Liu Y et al (2003) RNA interference in mammalian cells by chemicallymodified RNA. Biochemistry 42:7967-7975.
14. Brown PD, Bloxidge RE, Stuart NS et al (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578.
15. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
16. Chendrimada TP, Gregory RI, Kumaraswamy E et al (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436:740-744.
17. Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200:488-499.
18. Chiu YL, Rana TM (2003) siRNA function in RNAi: A chemical modification analysis. RNA 9:1034-1048.
19. Czubayko F, Schulte AM, Berchem GJ et al (1996) Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 93:14753-14758.
20. de Fougerolles A, Vornlocher HP, Maraganore J et al (2007) Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-453.
21. Doi N, Zenno S, Ueda R et al (2003) Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors. Curr Biol 13:41-46.
22. Donis-Keller H (1979) Site specific enzymatic cleavage of RNA. Nucleic Acids Res 7:179-192.
23. Donze O, Picard D (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 30:e46.
24. Dorsett Y, Tuschl T (2004) siRNAs: Applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3:318-329.
25. Dowler T, Bergeron D, Tedeschi AL et al (2006) Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res 34:1669-1675.
26. Dykxhoorn DM, Schlehuber LD, London IM et al (2006) Determinants of specific RNA interference- mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 103:5953-5958.
27. Elbashir SM, Harborth J, Lendeckel W et al (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
28. Elbashir SM, Lendeckel W, Tuschl T (2001b) RNA interference is mediated by 21- And 22- nucleotide RNAs. Genes Dev 15:188-200.
29. Elbashir SM, Martinez J, Patkaniowska A et al (2001c) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 20:6877- 6888.
30. Elbashir SM, Harborth J, Weber K et al (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213.
31. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391:806-811.
32. Forsyth PA, Wong H, Laing TD et al (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79:1828-1835.
33. Gaillard PJ, Visser CC, de Boer AG (2005) Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv 2:299-309.
34. Godbey WT, Wu KK, Mikos AG (1999) Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 45:268-275.
35. Gondi CS, Lakka SS, Dinh DH et al (2004) Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 1:165-176.
36. Gregory RI, Chendrimada TP, Cooch N et al (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123:631-640.
37. Grzelinski M, Bader N, Czubayko F et al (2005) Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer 117:942-951.
38. Grzelinski M, Urban-Klein B, Martens T et al (2006) RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17:751-766.
39. GrzelinskiM, Steinberg F, Martens T et al (2009) Enhanced anti-tumorigenic effects in glioblastoma on double targeting of pleiotrophin (PTN) and ist receptor ALK. Neoplasia 11:145-156.
40. Guo S, Kemphues KJ (1995) par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81:611-620.
41. Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286:950-952.
42. Hammond SM, Bernstein E, Beach D et al (2000) An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature 404:293-296.
43. Harborth J, Elbashir SM, Vandenburgh K et al (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105.
44. Heil F, Hemmi H, Hochrein H et al (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529.
45. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027.
46. Hobel S, Prinz R, Malek A et al (2008) Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm 70:29-41.
47. Holen T, Amarzguioui M, Wiiger MT et al (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 30:1757- 1766.
48. Judge AD, Sood V, Shaw JR et al (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457-462.
49. Kateb B, Van Handel M, Zhang L et al (2007) Internalization of MWCNTs by microglia: Possible application in immunotherapy of brain tumors. Neuroimage 37(Suppl 1):S9-S17.
50. Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216.
51. Kichler A (2004) Gene transfer with modified polyethylenimines. J Gene Med 6(Suppl 1):S3-S10.
52. Kim DH, Longo M, Han Y et al (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22:321-325.
53. Kim DH, Behlke MA, Rose SD et al (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23:222-226.
54. Kondraganti S, Gondi CS, McCutcheon I et al (2006) RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol 28:1353-1360.
55. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96.
56. Kumar P, Wu H, McBride JL et al (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43.
57. Kunath K, von Harpe A, Petersen H et al (2002) The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice. Pharm Res 19:810-817.
58. Kurihara A, Deguchi Y, Pardridge WM (1999) Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 10:502-511.
59. Laiho M, Keski-Oja J (1989) Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 49:2533-2553.
60. Lakka SS, Gondi CS, Dinh DH et al (2005) Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 280:21882-21892.
61. Lee NS, Dohjima T, Bauer G et al (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20:500-505.
62. Liu J, Carmell MA, Rivas FV et al (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-1441.
63. Mailleux P, Vanderwinden JM, Vanderhaeghen JJ (1992) The new growth factor pleiotrophin (HB-GAM) mRNA is selectively present in the meningothelial cells of human meningiomas. Neurosci Lett 142:31-35.
64. Malek A, Czubayko F, Aigner A (2008) PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target 16:124-139.
65. Malek A, Merkel O, Fink L et al (2009) Invivo Pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicology and App Pharm 236:97-108.
66. Mao S, Neu M, Germershaus O et al (2006) Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 17:1209-1218.
67. Martinez J, Patkaniowska A, Urlaub H et al (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563-574.
68. Mentlein R, Held-Feindt J (2002) Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem 83:747-753.
69. Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5:355-365.
70. Mohan PM, Chintala SK, Mohanam S et al (1999) Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 59:3369-3373.
71. Muller S, Kunkel P, Lamszus K et al (2003) A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22:6661-6668.
72. Nakagawara A, Milbrandt J, Muramatsu T et al (1995) Differential expression of pleiotrophin and midkine in advanced neuroblastoma. Cancer Res 55:1792-1797.
73. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2:279-289.
74. Neu M, Fischer D, Kissel T (2005) Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 7:992-1009.
75. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9-S15.
76. Niola F, Evangelisti C, Campagnolo L et al (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 5:174-179.
77. Ossowski L, Russo-Payne H, Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: The effect of dissemination of a human tumor in the nude mouse. Cancer Res 51:274-281.
78. Paddison PJ, Caudy AA, Bernstein E et al (2002) Short hairpin RNAs (shRNAs) induce sequencespecific silencing in mammalian cells. Genes Dev 16:948-958.
79. Pardridge WM (1998) CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70:1781-1792.
80. Pardridge WM(2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139.
81. Pardridge WM, Eisenberg J, Yang J (1985) Human blood-brain barrier insulin receptor. J Neurochem 44:1771-1778.
82. Parker JS, Roe SM, Barford D (2004) Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J 23:4727-4737.
83. Petersen H, Fechner PM, Fischer D et al (2002) Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers. Macromolecules 35:6867-6874.
84. Pham JW, Pellino JL, Lee YS et al (2004) A Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 117:83-94.
85. Powers C, Aigner A, Stoica GE et al (2002) Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 277:14153-14158.
86. Puduvalli VK (2004) Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 117:307-336.
87. Rao JS, Steck PA, Mohanam S et al (1993) Elevated levels of M(r) 92, 000 type IV collagenase in human brain tumors. Cancer Res 53:2208-2211.
88. Reynolds A, Leake D, Boese Q et al (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330.
89. Romano N, Macino G (1992) Quelling: Transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 6:3343-3353.
90. Satyamoorthy K, Oka M, Herlyn M (2000) An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res 13(Suppl 8):87-93.
91. Schiffelers RM, Ansari A, Xu J et al (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149.
92. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A et al (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129-139.
93. Schwarz DS, Hutvagner G, Du T et al (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208.
94. Silva GA (2007) Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg Neurol 67:113-116.
95. Siolas D, Lerner C, Burchard J et al (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227-231.
96. Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348:1079-1090.
97. Sledz CA, Holko M, de Veer MJ et al (2003) Activation of the interferon system by shortinterfering RNAs. Nat Cell Biol 5:834-839.
98. Sohail M, Doran G, Riedemann J et al (2003) A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res 31:e38.
99. Song JJ, Smith SK, Hannon GJ et al (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305:1434-1437.
100. Stoica GE, Kuo A, Powers C et al (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277:35990-35998.
101. Takano S, Tsuboi K, Tomono Y et al (2000) Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82:1967-1973.
102. Tan PH, Yang LC, Shih HC et al (2005) Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12:59-66.
103. Tang MX, Szoka FC (1997) The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 4:823-832.
104. Tummalapalli P, Gondi CS, Dinh DH et al (2007) RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 31:5-17.
105. Ulbricht U, Brockmann MA, Aigner A et al (2003) Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol 62:1265-1275.
106. Urban-Klein B, Werth S, Abuharbeid S et al (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-466.
107. Wagner E, Kircheis R, Walker GF (2004) Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed Pharmacother 58:152-161.
108. Weber D, Klomp HJ, Czubayko F et al (2000) Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 60:5284-5288.
109. Werth S, Urban-Klein B, Dai L et al (2006) A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release 112:257-270.
110. Xia CF, Zhang Y, Zhang Y et al (2007) Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 24:2309-2316.
111. Yamamoto M, Sawaya R, Mohanam S et al (1994) Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54:5016-5020.
112. Zamore PD, Tuschl T, Sharp PA et al (2000) RNAi: double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25-33.
113. Zhang Y, Boado RJ, Pardridge WM (2003) In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 5:1039-1045.
114. Zhang Y, Zhang YF, Bryant J et al (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10:3667-3677.
115. Zukiel R, Nowak S, Wyszko E et al (2006) Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 5:1002-1007.